^
Association details:
| Biomarker: | AR wild-type |
|---|---|
| Cancer: | Prostate Cancer |
| Drug: | Xtandi (enzalutamide) (Androgen receptor inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
1836P - Blood based biomarkers identify metastatic castration-resistant prostate cancer (mCRPC) with the greatest benefit from continuing enzalutamide (ENZ) beyond progression in combination with docetaxel (Doc): A pre-specified biomarker study of the phase IIIb PRESIDE trial
Published date:
10/16/2023
Excerpt:
Pt who were AR wt and AR-V7- (N=87, 55%) had significantly prolonged PFS from continuing ENZ (11.2 months (m) v 8.7 m P, HR: 0.49; 95% CI: 0.29-0.82, p=0.006)…
Trial ID:
Source:
Title:
1399P - Androgen receptor (AR) alterations on circulating tumor DNA (ctDNA) sequencing and response to the first-line androgen-receptor targeted agent (ARAT) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC)
Published date:
09/05/2022
Excerpt:
This was an IRB-approved retrospective study. Eligibility: confirmed diagnosis of mCRPC, first-line treatment with an ARAT (abiraterone or enzalutamide)....Median PFS and OS for AR wt was significantly higher than AR+ pts. In the subgroup analyses median PFS and OS were similar regardless of AR amp or AR mut....In this hypothesis-generating study, pts with mCRPC harboring AR alterations in ctDNA had worse outcomes on first-line ARAT compared to AR wt.
